MOLN Q4 2025 Earnings Positive EPS Surprise Highlights Cost Discipline Amid Clinical Progress TLK Q4 2025 Earnings EPS Misses Estimations Significantly Stock Declines 472 LOB Q1 2026 Earnings Strong EPS Beat Despite Modest Stock Pullback NervGen Pharma Q3 2025 Earnings Narrowed Loss Meets Estimates But Stock Plunges 43 CCL Q1 2026 Earnings EPS Surprises to the Upside as Cruise Demand Holds Steady ONBPP Q1 2026 Earnings Slight EPS Miss Amid Stable Performance